Tau Pathology Pathway in Alzheimer's Disease describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
The tau pathology pathway is central to Alzheimer's disease (AD) pathogenesis and represents one of the two hallmark proteinopathies in AD, alongside amyloid-beta (Aβ) plaques. Tau is a microtubule-associated protein that stabilizes neuronal axons under normal conditions. In AD and related tauopathies, tau undergoes pathological transformation including hyperphosphorylation, misfolding, oligomerization, and aggregation into neurofibrillary tangles (NFTs)[1]. The spread of tau pathology through connected brain regions correlates strongly with cognitive decline, making tau an attractive therapeutic target[2].
In the healthy brain, **tau protein (MAPT)** serves essential neuronal functions[3]:
The human MAPT gene produces six major tau isoforms through alternative splicing of exons 2, 3, and 10[4]:
| Isoform | Amino Acids | N-terminal Inserts | Microtubule Repeats |
|---|---|---|---|
| 2N4R | 441 | Both (N1, N2) | 4 (R1-R4) |
| 2N3R | 410 | Both | 3 (R1, R3, R4) |
| 1N4R | 432 | N1 only | 4 |
| 1N3R | 401 | N1 only | 3 |
| 0N4R | 383 | None | 4 |
| 0N3R | 352 | None | 3 |
The ratio of 3-repeat (3R) to 4-repeat (4R) tau is approximately 1:1 in the normal adult brain. This balance is disrupted in various tauopathies[5].
Tau phosphorylation is regulated by a balance of kinases and phosphatases. In AD, kinase activity predominates, leading to hyperphosphorylation[6].
Glycogen Synthase Kinase-3β (GSK-3β)
Cyclin-Dependent Kinase 5 (CDK5)
Mitogen-Activated Protein Kinases (MAPKs)
Protein Kinase A (PKA)
Tyrosine Kinases
The main phosphatase regulating tau phosphorylation is protein phosphatase 2A (PP2A)[12]:
Over 45 phosphorylation sites have been identified on tau. Key sites in AD include:
Early phosphorylation sites:
Late phosphorylation sites:
Hyperphosphorylated tau loses its ability to bind microtubules and gains aggregation propensity [14]:
Paired Helical Filaments (PHFs)
Straight Filaments (SFs)
3R vs 4R Tau Filaments
Growing evidence suggests different tau species have varying toxicity [17]:
Tau pathology spreads through connected brain regions in a stereotypical pattern:
| Stage | Region | Clinical Correlation |
|---|---|---|
| I-II | Transentorhinal cortex | Preclinical |
| III-IV | Limbic system (hippocampus, amygdala) | Mild cognitive impairment |
| V-VI | Neocortex | Moderate to severe dementia |
| Disease | Primary Tau | Key Regions |
|---|---|---|
| PSP | 4R | Basal ganglia, brainstem |
| CBD | 4R | Cortex, basal ganglia |
| FTD (MAPT) | 3R or 4R | Frontal/temporal cortex |
| AGD | 4R | Amygdala, hippocampus |
| PART | 3R/4R | Medial temporal lobe |
Pathogenic MAPT mutations cause frontotemporal dementia with parkinsonism (FTDP-17)[19]:
| Mutation | Type | Effect on Tau |
|---|---|---|
| P301L | Missense | Reduced microtubule binding, increased aggregation |
| P301S | Missense | Similar to P301L |
| V337M | Missense | Impaired microtubule assembly |
| R406W | Missense | Reduced phosphorylation, altered binding |
| N279K | Splicing | Increases 4R tau |
| 10+16 intronic | Splicing | Exon 10 inclusion, 4R tau |
While amyloid and tau pathology can occur independently, there is significant crosstalk[21]:
Microglial activation contributes to tau pathology[22]:
Tau pathology impacts mitochondrial function:
Active Vaccination
Passive Immunotherapy
Aggregation Inhibitors
Microtubule Stabilizers
Kinase Inhibitors
Tau accumulates in presynaptic terminals early in disease[32]:
Tau pathology affects neural networks:
Tau spreads trans-synaptically:
| Site | Kinase | Early/Late | Antibody |
|---|---|---|---|
| Ser199 | GSK-3β, CDK5 | Early | AT100 |
| Ser202/Thr205 | GSK-3β, CDK5 | Early | AT8 |
| Thr231 | GSK-3β | Early | AT180 |
| Ser396 | GSK-3β, PKA | Late | PHF13 |
| Ser404 | GSK-3β, PKA | Late | PHF1 |
| Tyr18 | Fyn | Late | PT18 |
Despite extensive efforts, tau-targeted therapies have faced challenges[35]:
Tau undergoes multiple post-translational modifications[36]:
Tau pathology represents the strongest correlate of cognitive decline in AD. While therapeutic targeting has proven challenging, advances in biomarker development and understanding of tau biology continue to inform drug development. The prion-like propagation of tau provides a framework for understanding disease progression and timing of interventions.
Astrocytes participate in tau pathology[40]:
Microglia interact with tau in multiple ways[^41]:
White matter involvement in tauopathies:
Tau causes neuronal death through multiple pathways[^43]:
Tau burden correlates with specific deficits:
Mechanisms of action:
Clinical trial outcomes:
GSK-3β inhibitors:
CDK5 inhibitors:
Small molecules:
Peptide-based inhibitors:
Mandelkow & Mandelkow. Tau in physiology and pathology. Nature Reviews Neuroscience. 2012. ↩︎
Arriagada et al. Neurofibrillary tangles correlate with dementia severity. Archives of Neurology. 1995. ↩︎
Wang & Mandelkow. Tau in physiology and pathology. Nature Reviews Neuroscience. 2016. ↩︎
Goedert et al. [ Multiple isoforms of human microtubule-associated protein tau](https://doi.org/10.1016/0896-6273(89). Neuron. 1989. ↩︎
Spillantini & Goedert. [ Tau protein pathology in neurodegenerative diseases](https://doi.org/10.1016/S1474-4422(13). Lancet Neurology. 2013. ↩︎
Hanger et al. Tau phosphorylation. Biochemical Society Transactions. 2014. ↩︎
Hooper. GSK-3 in tau pathology. Current Alzheimer Research. 2005. ↩︎
Cruz & Tsai. Cdk5 and tau in AD. Current Alzheimer Research. 2004. ↩︎
Zhu et al. MAPK and tau phosphorylation. Journal of Alzheimer's Disease. 2002. ↩︎
Liu et al. PKA and tau. Journal of Neurochemistry. 2006. ↩︎
Xia et al. Fyn and tau phosphorylation. Journal of Biological Chemistry. 2005. ↩︎
Liu et al. PP2A in tau hyperphosphorylation. Journal of Affective Disorders. 2019. ↩︎
Braak et al. Staging of tau pathology. Acta Neuropathologica. 1998. ↩︎
Fitzpatrick et al. Cryo-EM structures of tau filaments. Nature. 2017. ↩︎
Lasagna-Reeves et al. Tau oligomers. Alzheimer's & Dementia. 2011. ↩︎
Crowther. Paired helical filament tau. Current Opinion in Structural Biology. 1991. ↩︎
Cowburn et al. Tau oligomer toxicity. Biochemical Society Transactions. 2007. ↩︎
Frost & Diamond. Prion-like mechanisms in tau propagation. Cold Spring Harbor Perspectives in Medicine. 2012. ↩︎
Hutton et al. Association of missense and 5'-splice-site mutations in tau with FTDP-17. Nature. 1998. ↩︎
Pastor et al. MAPT H1 haplotype and AD. Annals of Neurology. 2000. ↩︎
Ittner & Götz. Amyloid-β and tau. Nature Reviews Neuroscience. 2011. ↩︎
Heneka et al. Neuroinflammation and tau. Nature Reviews Neurology. 2015. ↩︎
Amadoro et al. Tau and mitochondrial dysfunction. Journal of Alzheimer's Disease. 2010. ↩︎
Novak et al. AADvac1 phase 2 trial. Lancet Neurology. 2017. ↩︎
Mouton-Liger et al. Tau immunotherapy. Current Alzheimer Research. 2018. ↩︎
Wischik et al. Methylene blue derivatives. Proceedings of the National Academy of Sciences. 1996. ↩︎
Del Ser et al. Tideglusib in AD. Journal of Alzheimer's Disease. 2013. ↩︎
Zhang et al. Sodium selenate and tau. Journal of Alzheimer's Disease. 2014. ↩︎
Yuzwa & Vocadlo. O-GlcNAc and tau. Current Alzheimer Research. 2004. ↩︎
Schöll et al. Tau PET imaging. Nature Reviews Neurology. 2019. ↩︎
Janelidze et al. Plasma p-tau217. JAMA. 2020. ↩︎
Tai et al. Synaptic tau in AD. Acta Neuropathologica. 2012. ↩︎
Mably et al. Tau and network oscillations. Journal of Neuroscience. 2020. ↩︎
Wang et al. Exosomal tau in propagation. Acta Neuropathologica. 2017. ↩︎
Gandy & DeKosky. Tau therapeutic trials. Annals of Neurology. 2013. ↩︎
Morris et al. Tau post-translational modifications. Acta Neuropathologica. 2015. ↩︎
Wray. Tau truncation. Journal of Alzheimer's Disease. 2018. ↩︎
Morris et al. Tau and memory. Brain. 2013. ↩︎
Nedergaard & Goldman. Sleep and tau clearance. Neuron. 2020. ↩︎
Mandelkow et al. Axonal tau. Cellular and Molecular Life Sciences. 2006. ↩︎ ↩︎